{
    "nctId": "NCT02510781",
    "briefTitle": "A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs",
    "officialTitle": "A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis Detecting Circulating Tumor Cells",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 200,
    "primaryOutcomeMeasure": "pathological complete response rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 18\u2264aged\\<70\n* pathologic diagnosis of invasive breast cancer\uff0cstaging ii to iii\uff0cthe diameters\u22652cm indicated by MRI or axillary lymph node\uff08+\uff09\n* Immunohistochemical\uff08IHC\uff09 positive for 3+ or FISH\uff08+\uff09\n* clear hormone receptor\uff08HR\uff09 status\n* Eastern cooperative oncology group(ECOG)=0/1\n* LVEF\u226555%\n* pathologic grading of Miller and Payne\n* screening laboratory values with the following parameters\uff1aabsolute neutrophils acount\uff1a\u22651500/mm3,total bilirubin:\u22642.0\u00d7ULM,Aspartate transaminase (AST)/ALT\u22642.5\u00d7ULM,platelet\u226580000/mm3\uff0cserum creatinine\u22641.5\u00d7ULM\n* no pregnant or nursing\n* signed Informed consent forms\n\nExclusion Criteria:\n\n* prior exposure to any treatments for breast cancer\n* inflammatory/Bilateral/IV stage breast cancer\n* poor physical condition\n* pregnant or nursing\n* Cardiac risk\uff08Congestive heart failure\u3001arrhythmia\u3001myocardial infarct\u3001Refractory hypertension\uff08systolic pressure\\>180mmHg/diastolic pressure\\>100mmHg\uff09\uff09\n* any other cancer within 5 years prior to screening with the exception of cervical carcinoma and non melanoma skin cancer\n* Allergic to chemotherapy drugs",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}